Early-phase data for RMC-4630 have demonstrated preliminary activity in KRAS-mutant NSCLC, although adverse effects such as rash, fatigue, and gastrointestinal symptoms remain important considerations [161]. Here, KRAS is linked to non-small cell lung carcinoma.